



NC DEPARTMENT OF
**HEALTH AND
HUMAN SERVICES**

ROY COOPER • Governor
KODY H. KINSLEY • Secretary
MARK BENTON • Deputy Secretary for Health
SUSAN KANSAGRA • Assistant Secretary for Public Health
Division of Public Health

September 28, 2023

MEMORANDUM

TO: Vaccines for Children (VFC) Program Participants

FROM: Carrie Blanchard, PharmD, MPH
Interim Immunization Branch Director

SUBJECT: Respiratory Syncytial Virus (RSV) Vaccine Available for Ordering

This purpose of this memo is to let VFC-enrolled providers know that the monoclonal antibody product nirsevimab (trade name: BEYFORTUS™, Sanofi) is now available to order via the North Carolina Immunization Registry (NCIR).

BEYFORTUS™ Use

The monoclonal antibody product nirsevimab (trade name: BEYFORTUS™, Sanofi) was approved for the prevention of respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI) in all infants younger than age 8 months during their first RSV season and in some children at high risk of severe disease during their second RSV season.

BEYFORTUS™ is administered intramuscularly (IM), with three dosing options based upon the child's age and weight. Timing of BEYFORTUS™ administration is seasonal. Infants born during (or shortly before) the RSV season should be immunized within the first week of life (either before discharge from the delivery hospital or as an outpatient). Infants younger than 8 months of age who are born outside the season should receive BEYFORTUS™ shortly before, or early in, their first RSV season, and may be immunized when receiving other routine live or non-live vaccinations.

Dosing by Weight/Age

A single dose should be administered to

- Infants weighing <5 kg: 50 mg dose (NDC 49281-0575-15)
- Infants weighing ≥5 kg: 100 mg dose (NDC 49281-0574-15)
- Children receiving BEYFORTUS™ in their second RSV season should receive a single dose of 200 mg, administered through 2 separate 100 mg IM injections.

NC DEPARTMENT OF HEALTH AND HUMAN SERVICES • DIVISION OF PUBLIC HEALTH • IMMUNIZATION BRANCH

LOCATION: 5601 Six Forks Road, Raleigh, NC 27609
MAILING ADDRESS: 1917 Mail Service Center, Raleigh, NC 27699-1917
www.ncdhhs.gov • TEL: 919-707-5550 • FAX: 919-870-4824

AN EQUAL OPPORTUNITY / AFFIRMATIVE ACTION EMPLOYER

Dosing for Children at High Risk During Second RSV Season

Children ages 8-19 months who remain vulnerable to severe RSV disease when entering their second RSV season should receive a dose of BEYFORTUS™.

Please review ACIP's Recommendations, including the [MMWR on use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children](#), as well as the [package insert](#) for more information.

VFC Eligibility

Please note that doses obtained through the North Carolina Immunization Program are for [VFC eligible children only](#). Fully insured children must receive privately purchased BEYFORTUS™.

Birthing Hospitals

Currently, there is not a vital records feed for BEYFORTUS™ administrations; therefore, these doses will need to be documented directly in the North Carolina Immunization Registry (NCIR). If your hospital is currently on data exchange, these doses will transfer over automatically from your EHR. One of our data exchange Onboarding Specialists will reach out to your technical contacts to complete some minor testing. If your hospital is not on data exchange, your [Regional Immunization Consultant](#) will reach out to schedule NCIR onboarding and training. More information on ordering will be forthcoming.

If you have any questions or need assistance, please contact the Immunization Branch Help Desk at 1-877-873-6247.

Sincerely,



Carrie Blanchard, PharmD, MPH
Interim Immunization Branch Director